<DOC>
	<DOCNO>NCT02796651</DOCNO>
	<brief_summary>To assess bronchodilation three dos formoterol fumarate ( 6 μg , 12 μg 24 μg ) twice daily ( BID ) administer via Pressair® compare placebo open-label nebulized formoterol fumarate ( 20 μg 40 μg ) .</brief_summary>
	<brief_title>Formoterol Dose Ranging Study ( ACHIEVE Duaklir USA Phase IIb ) .</brief_title>
	<detailed_description>This prospective , randomize , double-blind , 5-period incomplete unbalance crossover , placebo active comparator ( open-label ) control , multicenter clinical trial ass efficacy safety three dos formoterol fumarate ( 6 μg , 12 μg 24 μg ) BID administer via Pressair® compare placebo open-label formoterol fumarate ( 20 μg BID 40 μg single dose ) administer inhalation solution via standard jet nebulizer ( mouthpiece ) connect air compressor ( Perforomist® Inhalation Solution ) . The drug product inhalation powder comprise micronized aclidinium bromide micronized formoterol fumarate α-lactose monohydrate carrier , present breathactuated device-metered dry-powder inhaler ( DPI ) . It approve trademark Genuair® and/or Pressair® territory .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Adult male nonpregnant , nonlactating female patient age ≥40 . Patients diagnosis COPD ( GOLD guideline , 2016 ) period least 6 month prior Visit 1 . Patients moderate severe stable COPD : postbronchodilator FEV1 ≥ 30 % &lt; 80 % predict normal postbronchodilator FEV1/FVC &lt; 70 % Visit 1 . Patients reversible airway obstruction define increase FEV1 least 12 % 200 mL baseline value four inhalation albuterol sulfate 108 µg via pMDI Visit 1 . Current formersmokers , smoke history ≥ 10 packyears . Patients able perform acceptable repeatable pulmonary function test FEV1 accord American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) 2005 criterion Visit 1 . Patients eligible able participate study sign Informed Consent Form prior initiation studyrelated procedure . Patients asthma . Any respiratory tract infection ( include upper respiratory tract ) COPD exacerbation ( include mild COPD exacerbation ) within 6 week prior Visit 1 runin period . Patients hospitalize COPD exacerbation ( emergency room visit longer 24 hour consider hospitalization ) within 3 month prior Visit 1 . Clinically significant respiratory condition COPD . Patients investigator 's opinion may need start pulmonary rehabilitation program study and/or patient started/finished within 3 month prior Visit 1 . Use longterm oxygen therapy ( ≥ 15 hours/day ) . Patients maintain regular day/night , waking/sleeping cycle include night shift worker . Clinically significant cardiovascular condition . Patients uncontrolled Type I Type II diabetes , uncontrolled hypoor hyperthyroidism , hypokalaemia , hyperadrenergic state , uncontrolled hypertension . Patients history long QT syndrome whose QTc ( calculate accord Fridericia 's Formula QTc=QT/RR1/3 ) &gt; 470 m indicate centralized reading report assess Visit 1 . Patients clinically significant abnormality laboratory test , ECG parameter ( QTc ) physical examination Visit 1 might compromise patient safety . Patients history hypersensitivity reaction inhale medication component thereof , include paradoxical bronchospasm . Patients know narrowangle glaucoma , symptomatic bladder neck obstruction , acute urinary retention symptomatic unstable prostate hypertrophy . History malignancy organ system ( include lung cancer ) , treat untreated , within past 5 year basal squamous cell skin cancer . Patients serious uncontrolled physical mental dysfunction . Patients history ( within 2 year prior screen ) drug and/or alcohol abuse may prevent study compliance base Investigator judgment . Patients unlikely cooperative comply study procedure . Patients treat investigational drug within 30 day ( 6 halflives , whichever long ) prior Visit 1 . Patients intend use concomitant medication permit protocol undergone require washout period particular prohibit medication . Patients unable give consent , patient consent age guardianship , vulnerable patient . Any condition , investigator 's opinion , might render patient unsuitable study . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or site staff ) , patient employ relative employee site sponsor . Previous randomization present study D6571C00002 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Perforomist</keyword>
	<keyword>Pressair</keyword>
	<keyword>COPD</keyword>
	<keyword>Cigarette smoking</keyword>
	<keyword>Formoterol fumarate</keyword>
	<keyword>long-acting β2-adrenergic agonist ( LABA )</keyword>
	<keyword>long-acting muscarinic antagonist ( LAMA )</keyword>
</DOC>